Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

(19)

(11)

EP 1 808 169 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	04.07.2012 Bulletin 2012/27

(45)	Mention of the grant of the patent:
	30.05.2012 Bulletin 2012/22

(21)	Application number: 07008782.0

(22)	Date of filing: 28.12.2000

(51)

International Patent Classification (IPC):

A61K 31/19^(2006.01)
A61K 31/05^(2006.01)
A61K 31/135^(2006.01)
A61K 31/235^(2006.01)
A61P 25/28^(2006.01)

A61K 31/35^(2006.01)
A61K 31/70^(2006.01)
A61K 31/165^(2006.01)
A61P 25/16^(2006.01)

(54)

Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

Polyhydroxylierte aromatische Verbindungen zur Behandlung von Amyloidose und $g(a)-Synuklein-Fibrillen-Erkrankungen

Composés aromatiques Polyhydroxylés pour le traitement des maladies fibrilles d'amylose et $g(a)-synucléines

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30)

Priority:

30.12.1999 US 173958
26.12.2000 US 748748

(43)	Date of publication of application:
	18.07.2007 Bulletin 2007/29

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	00989636.6 / 1244435

(73)	Proprietor: Proteotech Inc.
	Kirkland, WA 98034 (US)

(72)	Inventors:
	Castillo, Gerardo M. Seattle WA 98178 (US) Choi, Paula Y. Seattle, WA 98103 (US) Snow, Alan D. Lynnwood WA 98037 (US)

(74)	Representative: Crooks, Elizabeth Caroline
	Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ London WC1R 4PJ (GB)

(56)

References cited: :

EP-A- 0 287 341
WO-A-01/49307
WO-A-98/34646
JP-A- 01 151 514
US-A- 5 283 352

WO-A-00/07608
WO-A-98/09653
FR-A- 2 081 454
US-A- 3 729 563
US-A- 5 767 126

C. HERTEL ET. AL.: "Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid toxicity." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 94, no. 8, August 1997 (1997-08), pages 9412-6, XP001026042
H. NIWANO ET. AL.: "Inhibitory action of amyloid precursor protein against human Hageman Factor (Factor XII)." JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 125, no. 2, 1995, pages 251-6, XP000933861


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).